Journal
ANTIVIRAL THERAPY
Volume 15, Issue -, Pages 3-8Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1522
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Abbott Laboratories
- Gilead
- Janssen Pharmaceutica
- MSD
Ask authors/readers for more resources
Accurate estimates of HIV prevalence in Europe are hampered by incomplete reporting of new HIV diagnoses. Defining the epidemiology of late presentation is even more challenging. In Europe, the most common definitions of late presentation are based on CD4(+) T-cell counts, but there is little consistency among definitions. Thus, estimates of the incidence of late presentation vary widely between studies and across Europe, making comparative analysis difficult. Late presentation has been observed to be common in all demographic groups, but certain factors indicate greater risk for late presentation, including intravenous drug use, older age, foreign birth and non-White ethnicity. Standardizing the definition of late presentation will facilitate understanding, clinical research and, ultimately, effective treatment of late-presenting patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available